XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 29, 2023
Dec. 30, 2022
Current assets:    
Cash and cash equivalents $ 396,859 $ 501,195
Short-term investments 706,528 807,273
Trade receivables, net 248,113 214,784
Inventory 24,978 33,299
Prepaid expenses and other current assets 66,891 62,211
Total current assets 1,443,369 1,618,762
Long-term investments 811,680 756,731
Property and equipment, net 121,039 110,624
Deferred tax assets, net 230,990 231,110
Goodwill 63,684 63,684
Right-of-use assets and other 306,148 290,578
Total assets 2,976,910 3,071,489
Current liabilities:    
Accounts payable 26,450 32,667
Accrued compensation and benefits 81,398 77,158
Accrued clinical trial liabilities 62,842 65,072
Rebates and fees due to customers 54,374 50,350
Accrued collaboration liabilities 27,269 20,188
Other current liabilities 124,483 78,924
Total current liabilities 376,816 324,359
Long-term portion of operating lease liabilities 190,858 190,170
Other long-term liabilities 61,616 68,533
Total liabilities 629,290 583,062
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 310,970 and 323,951 at September 30, 2023, and December 31, 2022, respectively 311 324
Additional paid-in capital 2,487,370 2,536,849
Accumulated other comprehensive loss (14,012) (14,521)
Accumulated deficit (126,049) (34,225)
Total stockholders’ equity 2,347,620 2,488,427
Total liabilities and stockholders' equity $ 2,976,910 $ 3,071,489